Saccharomyces Cerevisiae Study

Validating Hyperbolic Field Effects on a Model Biological Organism

Who We Are?

This research is conducted by ASRP LLP (Baikonur, Kazakhstan), led by Denis Banchenko with experimentalist Valeria Ovsyannikova executing the laboratory protocol. We chose Saccharomyces cerevisiae — one of the most well-characterized model organisms in biology — for its rapid growth, measurable fermentation output, and decades of published reference data.

Our Mission

Our mission is to validate that hyperbolic field effects are reproducible across different biological systems, building a chain of evidence from cell-free plasma to living organisms. By demonstrating channel-specific bioactive effects in yeast, we strengthen the case that these phenomena are universal biological responses rather than artifacts of a single experimental model.

Project Goal

The goal is to confirm channel-specific bioactive effects in a living organism and create a reproducible protocol for biological field modulation research. Success means demonstrating statistically significant differences in yeast fermentation and viability across channels, producing publishable results under patent KZ 2025/1095.1 (Fractal Biomedical).

Research Components

Emitter Technology:

Description:

The emitter platform has been upgraded from the original 0.7W prototype to a 60W average / 144W peak system built around a 6-node array generating a clean sine wave output. This two-order-of-magnitude power increase ensures biologically relevant field intensities while maintaining signal purity critical for reproducible channel-specific effects.

Measurement Protocol:

Description:

Cell viability is assessed via methylene blue exclusion staining under light microscopy, providing a direct live/dead count at each time point. Fermentation kinetics are tracked at 3h, 6h, 12h, 24h, and 48h intervals, capturing both early metabolic onset and long-term culture behavior to map the full dose-response curve for each channel.

IP & Team:

Description:

This research is conducted under patent KZ 2025/1095.1 (Fractal Biomedical), filed by ASRP LLP, Baikonur, Kazakhstan. The study is led by Denis Banchenko with experimentalist Valeria Ovsyannikova executing the laboratory protocol. All methods and results are designed for future publication and independent replication.